system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: UNASSIGNED, METHODS, RESULTS. Meshes: Humans, Iodine Radioisotopes, Molecular Targeted Therapy, Neoplasms, Receptors, Somatostatin, Treatment Outcome, Tumor Cells, Cultured.
user
Does hIGHLY INCREASED 125I-JR11 ANTAGONIST BINDING IN VITRO reveal NOVEL INDICATIONS FOR SST2 TARGETING IN HUMAN CANCERS? Context: There is recent in vitro and in vivo evidence that somatostatin receptor sst2 antagonists are better tools to target neuroendocrine tumors (NET) than sst2 agonists. Indeed, antagonists bind to a greater number of sst2 sites than agonists. Whether sst2 antagonists could be used successfully to target non-NET tumors, expressing low sst2 density, is unknown. Here, we compare quantitatively  In vitro receptor autoradiography was performed with  In general, 
assistant
All RCC, a majority of breast cancers, NHL and medullary thyroid cancers represent novel indications for the in vivo radiopeptide targeting of sst2 by sst2 antagonists, comparable to NET radiotargeting with sst2 agonists. Final Decision: yes